Michael Gelband’s AstraZeneca AZN Stock Holding History

Michael Gelband’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-25,000	Closed	-$2.64M	–	1741
2020 Q2	$2.64M	Buy	+25,000	New	+$2.58M	0.07%	328

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Michael Gelband's AZN Position: Q2 2026 in Review

Michael Gelband sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 106,832 shares — an estimated $21.1M sold.

Michael Gelband first reported a position in AZN in Q1 2019 and held it in 18 quarters. The position peaked at $21.1M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Michael Gelband reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 106,832 AstraZeneca shares in Q2 2026, an estimated $21.1M.
Michael Gelband first reported a position in AstraZeneca in Q1 2019 and held it in 18 quarters.
Michael Gelband's AstraZeneca position peaked at $21.1M in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.